Class summary at a glance.

Every drug in the Parathyroid Hormone-Related Peptide Analog class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $426.7Mcombined across class
Total Rx claims: 144K32K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Abaloparatide

Brand: Tymlos · 144K Part D claims (CY24) · 32K beneficiaries · First FDA approval: 2017-05-01

Brand-only (no generics) 192 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $426.7M

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.